Cargando…

Efficacy and safety of clozapine in psychotic disorders—a systematic quantitative meta-review

A recent increase in the literature regarding the evidence base for clozapine has made it increasingly difficult for clinicians to judge “best evidence” for clozapine use. As such, we aimed at elucidating the state-of-the-art for clozapine with regard to efficacy, effectiveness, tolerability, and ma...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wagner, Elias, Siafis, Spyridon, Fernando, Piyumi, Falkai, Peter, Honer, William G., Röh, Astrid, Siskind, Dan, Leucht, Stefan, Hasan, Alkomiet
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8458455/ https://www.ncbi.nlm.nih.gov/pubmed/34552059 http://dx.doi.org/10.1038/s41398-021-01613-2

Ejemplares similares

T204. CLOZAPINE COMBINATION AND AUGMENTATION STRATEGIES IN PATIENTS WITH SCHIZOPHRENIA –RECOMMENDATIONS FROM AN INTERNATIONAL EXPERT SURVEY AMONG THE TREATMENT RESPONSE AND RESISTANCE IN PSYCHOSIS (TRRIP) WORKING GROUP
por: Wagner, Elias, et al.
Publicado: (2020)

S47. ADD-ON SPIRONOLACTONE FOR THE TREATMENT OF SCHIZOPHRENIA (SPIRO TREAT)
por: Roeh, Astrid, et al.
Publicado: (2018)

Clozapine in severe psychotic disorders: Balancing safety with efficacy
por: Leite, R. Almeida, et al.
Publicado: (2021)

Efficacy of clozapine compared with other second-generation antipsychotic drugs in patients with treatment-resistant schizophrenia: protocol for a systematic review and individual patient data meta-analysis of randomised controlled trials
por: Siafis, Spyridon, et al.
Publicado: (2023)

CLOZAPINE FOR PSYCHOTIC AND BEHAVIOURAL PROBLEMS IN DEMENTIA
por: Srinivasan, T.N.
Publicado: (1999)

Clozapine-induced Gastrointestinal Hypomotility — New Objective Evidence for an Underestimated Side-effect()
por: Hasan, Alkomiet
Publicado: (2016)

Evaluation of evidence grades in psychiatry and psychotherapy guidelines
por: Löhrs, Lisa, et al.
Publicado: (2020)

Erkennen und behandeln von Antipsychotika-Nebenwirkungen
por: Hasan, Alkomiet, et al.
Publicado: (2022)

M201. MODERATORS OF WEIGHT GAIN IN RANDOMIZED CONTROLLED TRIALS OF SCHIZOPHRENIA – A META-REGRESSION ANALYSIS
por: Schneider-Thoma, Johannes, et al.
Publicado: (2020)

T200. METABOLIC SIDE EFFECTS OF ANTIPSYCHOTIC DRUGS – PROTOCOL OF A SYSTEMATIC REVIEW AND NETWORK- METAANALYSIS
por: Schneider-Thoma, Johannes, et al.
Publicado: (2020)

Effects of Early Clozapine Treatment on Remission Rates in Acute Schizophrenia (The EARLY Trial): Protocol of a Randomized-Controlled Multicentric Trial
por: Wagner, Elias, et al.
Publicado: (2023)

Nonpharmacological treatment of dyscognition in schizophrenia: effects  of aerobic exercise 
por: Maurus, Isabel, et al.
Publicado: (2019)

Structured implementation of digital, systematically updated guideline recommendations for enhanced adherence in schizophrenia (SISYPHOS)—protocol of a cluster-randomized trial
por: Lorenz, Carolin, et al.
Publicado: (2022)

Guideline for schizophrenia: implementation status and attitude toward an upcoming living guideline
por: Khorikian-Ghazari, Naiiri, et al.
Publicado: (2023)

The relationship between blood–brain barrier dysfunction and neurocognitive impairments in first-episode psychosis: findings from a retrospective chart analysis
por: Maurus, Isabel, et al.
Publicado: (2023)

¿Do we prescribe less clozapine to immigrant psychotic patients compared to non-immigrant psychotic patients?
por: Trabsa, A., et al.
Publicado: (2022)

A case study evaluating the use of clozapine in depression with psychotic features
por: Jeyapaul, Premkumar, et al.
Publicado: (2006)

Imputing the Number of Responders from the Mean and Standard Deviation of CGI-Improvement in Clinical Trials Investigating Medications for Autism Spectrum Disorder
por: Siafis, Spyridon, et al.
Publicado: (2021)

Metformin for Clozapine Associated Obesity: A Systematic Review and Meta-Analysis
por: Siskind, Dan J., et al.
Publicado: (2016)

41.1 WHAT DO META-ANALYSES TELL US ABOUT CLOZAPINE’S EFFICACY AND EFFECTIVENESS FOR TREATMENT REFRACTORY SCHIZOPHRENIA?
por: Siskind, Dan, et al.
Publicado: (2018)

Pain, affect and psychotic illness
por: Möller, H.-J., et al.
Publicado: (2011)

Informing the development of a decision aid: Expectations and wishes from service users and psychiatrists towards a decision aid for antipsychotics in the inpatient setting
por: Müller, Katharina, et al.
Publicado: (2023)

Estimating and visualising the trade-off between benefits and harms on multiple clinical outcomes in network meta-analysis
por: Chiocchia, Virginia, et al.
Publicado: (2023)

Clozapine levels and therapeutic response: using individual patient meta-analysis data for a ROC Curve analysis
por: Northwood, K., et al.
Publicado: (2023)

Treatment strategies for clozapine-induced hypotension: a systematic review
por: Tanzer, Timothy David, et al.
Publicado: (2022)

Augmentation of Clozapine with Aripiprazole in Severe Psychotic Bipolar and Schizoaffective Disorders: A Pilot Study
por: Benedetti, Alessandra, et al.
Publicado: (2010)

Clozapine-Encapsulated Binary Mixed Micelles in Thermosensitive Sol–Gels for Intranasal Administration
por: Tan, Madeleine S. A., et al.
Publicado: (2022)

Decreased Serum Brain-Derived Neurotrophic Factor Concentrations 72 Hours Following Marathon Running
por: Roeh, Astrid, et al.
Publicado: (2021)

T44. 12-MONTH FOLLOW UP OF METABOLIC MEASURES FOLLOWING A RANDOMISED CONTROLLED TRIAL OF TREATMENT OF CLOZAPINE ASSOCIATED OBESITY AND DIABETES WITH EXENATIDE (CODEX)
por: Siskind, Dan, et al.
Publicado: (2020)

Psychiatric medication and physical performance parameters – Are there implications for treatment?
por: Hirschbeck, Anna, et al.
Publicado: (2022)

T160. TREATMENT OF CLOZAPINE-ASSOCIATED OBESITY AND DIABETES WITH EXENATIDE (CODEX) IN ADULTS WITH SCHIZOPHRENIA: A RANDOMISED CONTROLLED TRIAL
por: Siskind, Dan, et al.
Publicado: (2018)

Schizophrenia as a disorder of disconnectivity
por: Schmitt, Andrea, et al.
Publicado: (2011)

The impact of environmental factors in severe psychiatric disorders
por: Schmitt, Andrea, et al.
Publicado: (2014)

Reducing antipsychotic drugs in stable patients with chronic schizophrenia or schizoaffective disorder: a randomized controlled pilot trial
por: Huhn, Maximilian, et al.
Publicado: (2020)

Antipsychotic dose, dopamine D2 receptor occupancy and extrapyramidal side-effects: a systematic review and dose-response meta-analysis
por: Siafis, Spyridon, et al.
Publicado: (2023)

Optimising plasma clozapine levels to improve treatment response: an individual patient data meta-analysis and receiver operating characteristic curve analysis
por: Northwood, Korinne, et al.
Publicado: (2023)

Subjective burden and perspectives of German healthcare workers during the COVID-19 pandemic
por: Kramer, Victoria, et al.
Publicado: (2020)

Depression in Somatic Disorders: Is There a Beneficial Effect of Exercise?
por: Roeh, Astrid, et al.
Publicado: (2019)

Clozapine as a first‐ or second‐line treatment in schizophrenia: a systematic review and meta‐analysis
por: Okhuijsen‐Pfeifer, C., et al.
Publicado: (2018)

A Focused Review of the Metabolic Side-Effects of Clozapine
por: Yuen, Jessica W. Y., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_44jqrr5pcbk2n2gb0qhvnb1p8a